Nigerian pharma tycoon Fidelis Ayebae's Fidson receives support to expand production capacity
The collaboration with NEXIM is expected to position Fidson for a stronger presence in Africa's rapidly expanding pharmaceutical market.
The collaboration with NEXIM is expected to position Fidson for a stronger presence in Africa's rapidly expanding pharmaceutical market.
This move aligns with the company’s efforts to bolster Nigeria’s self-sufficiency in healthcare, focusing on combating the country's ongoing HIV crisis.
The deal is part of a broader initiative to enhance self-sufficiency in Africa’s healthcare infrastructure, particularly in the battle against HIV.
The surge in revenue is linked to the heightened sales of ethical products, including infusions, capsules, and tablets.
Ayebae, a banker turned accomplished industrialist, owns a 33.1-percent stake in the pharmaceutical company, which translates to 759,643,749 ordinary shares.
The recent gains solidify Ayebae’s position as one of Africa’s pharmaceutical industry magnates.
Ayebae owns an impressive 33.1-percent stake in Fidson Healthcare.
Under Ayebae’s guidance, Fidson Healthcare has achieved exceptional financial growth, reporting a significant increase in profits for the 2022 fiscal year.
Fidson Healthcare has established itself as a leading player in the Nigerian and West African pharmaceutical industries.